We are live on ! Find out more
CRL icon

Charles River Laboratories

407 hedge funds and large institutions have $5.16B invested in Charles River Laboratories in 2018 Q4 according to their latest regulatory filings, with 77 funds opening new positions, 117 increasing their positions, 155 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

215% more call options, than puts

Call options by funds: $18.3M | Put options by funds: $5.82M

141% more first-time investments, than exits

New positions opened: 77 | Existing positions closed: 32

11% more funds holding

Funds holding: 366407 (+41)

2.02% less ownership

Funds ownership: 97.11%95.09% (-2%)

18% less capital invested

Capital invested by funds: $6.27B → $5.16B (-$1.11B)

25% less repeat investments, than reductions

Existing positions increased: 117 | Existing positions reduced: 155

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

Holders
407
Holders Change
+41
Holders Change %
+11.2%
% of All Funds
9.07%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.07%
New
77
Increased
117
Reduced
155
Closed
32
Calls
$18.3M
Puts
$5.82M
Net Calls
+$12.5M
Net Calls Change
+$931K
Name Holding Trade Value Shares
Change
Change in
Stake
SPIO
276
Seven Post Investment Office
California
$410K
LTFS
277
Ladenburg Thalmann Financial Services
Florida
$394K +$218K +1,745 +101%
SCM
278
Shelton Capital Management
Colorado
$390K
BHWM
279
Bar Harbor Wealth Management
New Hampshire
$389K -$15.9K -127 -4%
OC
280
Oppenheimer & Co
New York
$374K -$31.2K -249 -7%
NERM
281
New England Research & Management
Illinois
$373K -$939K -7,500 -69%
GH
282
GAM Holding
Switzerland
$372K -$81.9K -654 -16%
SAM
283
Sawgrass Asset Management
Florida
$370K +$45.7K +365 +13%
RCM
284
Riverhead Capital Management
Delaware
$365K -$93.9K -750 -19%
PP
285
Paloma Partners
Connecticut
$353K -$549K -4,386 -58%
CI
286
CX Institutional
Indiana
$351K +$388K +3,100 New
HIMCH
287
Hartford Investment Management Co (HIMCO)
Connecticut
$344K
KeyBank National Association
288
KeyBank National Association
Ohio
$341K -$8.01K -64 -2%
IB
289
Intrust Bank
Kansas
$333K +$75K +599 +26%
LIA
290
LS Investment Advisors
Michigan
$326K -$100K -802 -22%
ACI
291
AMP Capital Investors
Australia
$325K +$364K +2,911 New
MC
292
Menta Capital
California
$315K -$1.01M -8,039 -74%
GSIS
293
Global Strategic Investment Solutions
Arizona
$310K +$343K +2,740 New
LSCM
294
LaSalle Street Capital Management
Illinois
$308K -$171K -1,367 -33%
GIA
295
Gateway Investment Advisers
Ohio
$303K +$8.51K +68 +3%
OPPM
296
Opus Point Partners Management
New York
$302K -$20.2K -161 -6%
CNBT
297
Canandaigua National Bank & Trust
New York
$295K -$54.5K -435 -14%
ECM
298
Element Capital Management
New York
$291K -$32.8K -262 -9%
MOS
299
MGO One Seven
Ohio
$282K -$33.4K -267 -10%
BC
300
Brinker Capital
Pennsylvania
$266K -$15.8K -126 -5%

CRL Hedge Fund Activity: Q4 2018 in Review

407 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q4 2018, worth a combined $5.16B — down 18% from $6.27B a quarter earlier.

Buyers outnumbered sellers: 77 funds opened new CRL positions and 32 closed out — a net gain of 45 holders — while 117 added to existing stakes and 155 trimmed.

The largest buyer was Epoch Investment Partners, opening a new position worth an estimated $43.1M. The largest seller was Fidelity International, cutting an estimated $96.6M.

  • 407 institutional investors held Charles River Laboratories (CRL) as of Q4 2018, up from 366 in Q3 2018.
  • Funds reported $5.16B of Charles River Laboratories stock for Q4 2018, down 18% quarter-over-quarter.
  • 77 funds opened new Charles River Laboratories positions in Q4 2018 and 32 closed out, a net change of +45 holders.
  • The largest Charles River Laboratories buyer in Q4 2018 was Epoch Investment Partners, an estimated $43.1M added.
  • The largest Charles River Laboratories seller in Q4 2018 was Fidelity International, an estimated $96.6M sold.

Based on aggregated 13F filings for Q4 2018.